Evidence of stereoselective and segmental-dependant transport of chiral antidiabetic drug nateglinide along the rat small intestine: Possible role of efflux transporters

Medicinal Chemistry Research

Volumn 22, Issue 5, 2013, Pages 2403-2410

  Maddi, Srinivas ^a,b,c   Yamsani, Shravan Kumar ^a   Devandla, Adukondalu ^a   Scriba, Gerhard ^b   Yamsani, Madhusudan Rao ^a  

^a KAKATIYA UNIVERSITY   (India)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c SYNGENE INTERNATIONAL LTD   (India)

Author keywords

Efflux transporters; Everted gut sac; Nateglinide; Regioselectivity; Stereoselectivity

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; NATEGLINIDE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG TRANSPORT; DUODENUM; EFFUSION; ENANTIOMER; GASTROINTESTINAL TRACT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ILEUM; INTESTINE ABSORPTION; JEJUNUM; MALE; NONHUMAN; RACEMIC MIXTURE; RAT; SMALL INTESTINE; STEREOCHEMISTRY;

EID: 84879685852     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0234-4     Document Type: Article

References (27)

1. Benet LZ, Cummins CL (2001) The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50(suppl 1):S3-S11
2. Benet LZ, Wu CY, Heberet MF, Wacher VJ (1996) Intestinal drug metabolism and anti transport process: a potential paradigm shift in oral drug delivery. J Control Release 39:139-143
3. Benet LZ, Takashi I, Yuanchao Z, Jeffrey AS, Vincet JW (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 62:25-31
4. Chinale J, Vollrath V, Wielandt AM, Mirinda S, Gonzalez R, Fresno AM, Quintana C, Gonzalez S, Andrade L, GuzMan S (1995) Differences between nuclear run-off and mRNA levels for multidrug resistance gene expression in the cephalocaudal axis of the mouse intestine. Biochim Biophys Acta 1264:369-376
5. Cummins CL, Jacobsen W, Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045
6. Devineni D, Walter YH, Smith HT, Lee JS, Prasad P, McLeod JF (2003) Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 43:163-170
7. Dornhost A (2001) Insulinotropic meglitinide analogues. Lancet 358:1709-1716
8. Drescher S, Glasser H, Mürdter T, Hitzl M, Eichelbaum M, Fromm MF (2003) P-glycoprotein mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 73:223-231
9. Fojo AT, Ueda K, Salmon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug resistance gene in human tumours and tissues. Proc Natl Acad Sci 84:265-269
10. Fricker G, Drewe J, Huwyler J, Guttman H, Beglinger C (1996) Relevance of P-glycoprotein for the enteral absorption of cyclosporine A: in vitro-in vivo correlation. Br J Pharmacol 118:1841-1847
11. Fromm MF (2000) P-glycoprotein: a defence mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69-74
12. Fromm MF (2003) Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33:6-9
13. Garrigues A, Escarguil AE, Orlowski S (2002) The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci 99:10347-10542
14. Halas CJ (2001) Nateglinide. Am J Health Syst Pharm 58:1200-1205
15. Hochman JH, Yamazaki M, Ohe T, Lin JH (2002) Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr Drug Matab 3:257-273
16. Hu S, Wang S, Dunning BE (2001) Glucose dependent and glucose sensitizing insulinotropic effect of nateglinide comparison to sulphonyl ureas and repaglinide. Int J Exp Diabetes Res 2:63-72
17. Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, Takamitsu Y (2003) Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 60:90-95
18. Koepsell H (1998) Organic cation transporters in intestine, kidney, liver and brain. Ann Rev Physiol 6:243-266
19. Litman T, Druely TE, Stien WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959
20. Okamura A, Emoto A, Koyabu N, Ohtani H, Sawada Y (2002) Transport and uptake of nateglinide in caco-2 cells and in its inhibitory effect on human monocarboxylate transporter MCT. Br J Pharmacol 137:391-399
21. Ruan LP, Chen S, Yu BY, Zhu DN, Cordell GA, Qiu SX (2006) Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. Eur J Med Chem 41:605-610
22. Shinkai H, Nishikawa M, Sato Y, Toi K, Kumashiro I, Seto Y, Fukuma M, Dan K, Toyoshima S (1989) N-(Cyclohexylcarbonyl)-d-phenylalanines and releated compounds, a new class of oral hypoglycemic agents. J Med Chem 32:1436-1441
23. Trezise AE, Romano PR, Gill DR, Hyde SC, Sepulveda FV, Buch wald M, Higgins CF (1992) The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J 11:4291-4303
24. Wacher VJ, Silverman JA, Yuancho Z, Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 11:1322-1330
25. Watkins PB (1997) The barrier functions of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170
26. Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, McLeod JF, Mangold JB (2001) Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 29:415-421
27. Yumoto R, Murakami T, Ryoko Y, Teruo M, Yuko N, Risa H, Junya N, Mikihisa T (1999) Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289:149-155